322 related articles for article (PubMed ID: 34079375)
21. Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma.
Huang JX; Liu B; Li Y; Li X; Ding LJ; Wang NY
Front Oncol; 2023; 13():1204486. PubMed ID: 37664019
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.
Xu Y; Fu S; Liu K; Mao Y; Wu J
Ther Clin Risk Manag; 2023; 19():853-863. PubMed ID: 37899984
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization.
Shi Q; Huang P; Zhang Z; Zhang W; Liu L; Yan Z
J Hepatocell Carcinoma; 2023; 10():1861-1871. PubMed ID: 37885925
[TBL] [Abstract][Full Text] [Related]
24. Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus.
Chang X; Yu S; Pang J; Zhang W; Kong H; Huang J; Zhang G; Zhang H; Gu Y; Chen Y; Yang B; Liu J; Zeng Z
J Hepatocell Carcinoma; 2023; 10():847-861. PubMed ID: 37304208
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
26. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China.
Zhu Y; Sun P; Wang K; Xiao S; Cheng Y; Li X; Wang B; Li J; Yu W; Cheng Y
Cancer Cell Int; 2021 Sep; 21(1):503. PubMed ID: 34537075
[TBL] [Abstract][Full Text] [Related]
28. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
29. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.
Ji X; Xu Z; Sun J; Li W; Duan X; Wang Q
Radiat Oncol; 2023 Jun; 18(1):101. PubMed ID: 37308914
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
[TBL] [Abstract][Full Text] [Related]
31. Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
Muto H; Kuzuya T; Kawabe N; Ohno E; Funasaka K; Nagasaka M; Nakagawa Y; Miyahara R; Shibata T; Hashimoto S; Katano Y; Hirooka Y
Anticancer Res; 2023 Oct; 43(10):4673-4682. PubMed ID: 37772587
[TBL] [Abstract][Full Text] [Related]
32. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
[TBL] [Abstract][Full Text] [Related]
33. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
34. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.
Li T; Guo J; Liu Y; Du Z; Guo Z; Fan Y; Cheng L; Zhang Y; Gao X; Zhao Y; He X; Wu W; Gao N; Wu Y; Li J; Zhang Y; Kang W; Cai Z; Wang W; Li X; Zan Y; Nguyen MH; Ji F
Cancer Immunol Immunother; 2023 Jul; 72(7):2137-2149. PubMed ID: 36840762
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer.
Xu M; Meng X; Lu Y; Wang F
J Gastrointest Oncol; 2022 Apr; 13(2):548-558. PubMed ID: 35557572
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.
Xu MH; Huang C; Li ML; Zhu XD; Tan CJ; Zhou J; Fan J; Sun HC; Shen YH
Cancer Med; 2023 Apr; 12(8):9202-9212. PubMed ID: 36790032
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of lenvatinib combined with PD‑1/PD‑L1 inhibitors in the treatment of hepatocellular carcinoma: A meta‑analysis and systematic review.
Zhang B; Su L; Lin Y
Oncol Lett; 2024 Jul; 28(1):312. PubMed ID: 38803443
[TBL] [Abstract][Full Text] [Related]
40. A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.
Gan L; Lang M; Tian X; Ren S; Li G; Liu Y; Han R; Zhu K; Li H; Wu Q; Cui Y; Zhang W; Fang F; Li Q; Song T
J Hepatocell Carcinoma; 2023; 10():673-686. PubMed ID: 37125392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
